Growth Metrics

Novartis Ag (NVSEF) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $3.4 billion.

  • Novartis Ag's Non-Current Deferred Tax Liability rose 4042.99% to $3.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.4 billion, marking a year-over-year increase of 4042.99%. This contributed to the annual value of $3.4 billion for FY2025, which is 4042.99% up from last year.
  • Latest data reveals that Novartis Ag reported Non-Current Deferred Tax Liability of $3.4 billion as of Q4 2025, which was up 4042.99% from $2.2 billion recorded in Q3 2025.
  • Over the past 5 years, Novartis Ag's Non-Current Deferred Tax Liability peaked at $7.5 billion during Q2 2021, and registered a low of -$276.0 million during Q1 2022.
  • Over the past 5 years, Novartis Ag's median Non-Current Deferred Tax Liability value was $2.5 billion (recorded in 2023), while the average stood at $2.6 billion.
  • Per our database at Business Quant, Novartis Ag's Non-Current Deferred Tax Liability crashed by 79032.26% in 2022 and then skyrocketed by 108804.35% in 2023.
  • Novartis Ag's Non-Current Deferred Tax Liability (Quarter) stood at $3.1 billion in 2021, then dropped by 12.51% to $2.7 billion in 2022, then dropped by 16.31% to $2.2 billion in 2023, then grew by 7.61% to $2.4 billion in 2024, then surged by 40.43% to $3.4 billion in 2025.
  • Its Non-Current Deferred Tax Liability stands at $3.4 billion for Q4 2025, versus $2.2 billion for Q3 2025 and $2.3 billion for Q2 2025.